FY2024 EPS Estimates for Schrödinger Cut by Leerink Partnrs

Schrödinger, Inc. (NASDAQ:SDGR) – Research analysts at Leerink Partnrs cut their FY2024 EPS estimates for Schrödinger in a note issued to investors on Tuesday, November 12th. Leerink Partnrs analyst M. Foroohar now forecasts that the company will post earnings of ($1.99) per share for the year, down from their prior forecast of ($1.78). The consensus estimate for Schrödinger’s current full-year earnings is ($2.19) per share. Leerink Partnrs also issued estimates for Schrödinger’s Q4 2024 earnings at $0.03 EPS, FY2025 earnings at ($2.10) EPS, FY2026 earnings at ($2.44) EPS, FY2027 earnings at ($2.60) EPS and FY2028 earnings at ($0.89) EPS.

SDGR has been the topic of a number of other reports. BMO Capital Markets raised their price target on Schrödinger from $25.00 to $28.00 and gave the stock an “outperform” rating in a research note on Wednesday. Morgan Stanley cut their price objective on shares of Schrödinger from $43.00 to $30.00 and set an “equal weight” rating on the stock in a report on Wednesday, August 21st. Three equities research analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $32.90.

Schrödinger Stock Down 7.8 %

Shares of NASDAQ:SDGR opened at $20.37 on Friday. The business has a fifty day simple moving average of $18.76 and a 200-day simple moving average of $20.42. Schrödinger has a 52 week low of $16.67 and a 52 week high of $38.00.

Schrödinger (NASDAQ:SDGR) last released its earnings results on Tuesday, November 12th. The company reported ($0.52) EPS for the quarter, missing the consensus estimate of ($0.40) by ($0.12). Schrödinger had a negative return on equity of 35.77% and a negative net margin of 91.84%. The firm had revenue of $35.30 million during the quarter, compared to analysts’ expectations of $41.25 million. During the same period in the previous year, the firm posted ($0.86) earnings per share. The firm’s revenue was down 17.1% on a year-over-year basis.

Institutional Trading of Schrödinger

Several large investors have recently added to or reduced their stakes in SDGR. Nisa Investment Advisors LLC lifted its stake in shares of Schrödinger by 145.3% during the second quarter. Nisa Investment Advisors LLC now owns 1,413 shares of the company’s stock worth $27,000 after purchasing an additional 837 shares in the last quarter. GAMMA Investing LLC raised its holdings in shares of Schrödinger by 49.5% during the 2nd quarter. GAMMA Investing LLC now owns 2,124 shares of the company’s stock valued at $41,000 after buying an additional 703 shares during the period. KBC Group NV lifted its position in Schrödinger by 45.4% during the 3rd quarter. KBC Group NV now owns 2,508 shares of the company’s stock worth $47,000 after acquiring an additional 783 shares in the last quarter. nVerses Capital LLC acquired a new position in Schrödinger during the 2nd quarter worth approximately $66,000. Finally, Quest Partners LLC boosted its holdings in Schrödinger by 1,005.6% in the 2nd quarter. Quest Partners LLC now owns 4,555 shares of the company’s stock worth $88,000 after acquiring an additional 4,143 shares during the period. 79.05% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Schrödinger

In related news, insider Margaret Dugan sold 1,531 shares of Schrödinger stock in a transaction on Tuesday, October 15th. The shares were sold at an average price of $17.78, for a total transaction of $27,221.18. Following the transaction, the insider now owns 13,469 shares in the company, valued at approximately $239,478.82. The trade was a 10.21 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Company insiders own 8.60% of the company’s stock.

Schrödinger Company Profile

Schrödinger, Inc, together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries.